Pro-Inflammatory Biomarkers and Long Term Neurological Outcomes in Hypothermia Plus Melatonin Treated Newborns. A Pilot Clinical Trial
Authors:
- Antonio Jerez-CaleroAJAntonio Jerez-Calero
- Francisco Contreras-ChovaFCFrancisco Contreras-Chova
- Angela Benitez-FeliponiABAngela Benitez-Feliponi
- Hatim AzaryahHAHatim Azaryah
- Jose Antonio Hurtado-SuazoJHJose Antonio Hurtado-Suazo
- M. Fernanda Moreno-GaldóMMM. Fernanda Moreno-Galdó
- Antonio Molina-CarballoAMAntonio Molina-Carballo
Preprint
- 11 April 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Objective. To evaluate serum neuronal and inflammatory biomarkers in asphyctic newborns treated with hypothermia alone or hypothermia plus melatonin, and whether biomarkers correlate with neurodevelopmental outcomes. Design. This is a pilot multicentre, randomised, controlled, double blind clinical trial. Neuronal glial fibrillary acidic protein (GFAP), granulocyte-macrophage colony-stimulating factor (GM-CSF), and inflammatory cytokines (interleukin (IL)-1, IL-2, IL-7 and IL-13) were measured in serum samples at hospital admission (T0), 24 hours (T1), 72 hours (T2) and 7-10 days of age (T3). Neurodevelopmental outcomes (Bayley Scales of Infant and Toddler Development-III scales, Gross Motor Function Classification System (GMFCS) and the Tardieu scale) were performed at 6 and 18 months. Setting: Level 3 neonatal intensive care unit. Patients and interventions: 25 newborns were recruited. The treated patients received a daily dose of intravenous melatonin, 5 mg per kg body weight, for 3 days. Results. After adjusting the data for severity, in the group treated with melatonin, there is a decrease in plasma levels of GM-CSF, IL-2 and IL-13 at T1 compared to placebo, as well as, at T2, in GM-CSF concentrations, as well as IL-7 and IL-13 at T3. Evolutionarily, we found a significant decrease in GM-CSF concentrations in the treatment group compared to placebo, with no differences for the rest of the biomarkers. It is noteworthy that the sustained decrease in GM-CSF and inflammatory cytokines IL-2, IL-7 and IL-13 correlated with better neurodevelopmental outcomes at 6 and 18 months. Conclusions. In neonates with hypoxic-ischemic encephalopathy, the addition of iv melatonin to hypothermia therapy affects the plasma concentration of biomarkers in the first week of life, with a high correlation with long-term neurological prognosis.Keywords
All Related Versions
This publication has 73 references indexed in Scilit:
- Association of High-Dose Erythropoietin With Circulating Biomarkers and Neurodevelopmental Outcomes Among Neonates With Hypoxic Ischemic EncephalopathyJAMA Network Open, 2023
- Evaluation of Glial and Neuronal Blood Biomarkers Compared With Clinical Decision Rules in Assessing the Need for Computed Tomography in Patients With Mild Traumatic Brain InjuryJAMA Network Open, 2022
- New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathyEuropean Journal of Pediatrics, 2021
- Melatonin exerts a neuroprotective effect against γ-radiation-induced brain injury in the rat through the modulation of neurotransmitters, inflammatory cytokines, oxidative stress, and apoptosisEnvironmental Science and Pollution Research, 2021
- Inhibiting ER Stress Weakens Neuronal Pyroptosis in a Mouse Acute Hemorrhagic Stroke ModelMolecular Neurobiology, 2020
- Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic ReviewsCochrane Database of Systematic Reviews, 2018
- Does the administration of melatonin during post-traumatic brain injury affect cytokine levels?Inflammopharmacology, 2017
- Cooling for newborns with hypoxic ischaemic encephalopathyCochrane Database of Systematic Reviews, 2013
- Melatonin is able to delay endoplasmic reticulum stress-induced apoptosis in leukocytes from elderly humansAGE, 2010
- Enhanced IL‐1β production in response to the activation of hippocampal glial cells impairs neurogenesis in aged miceSynapse, 2010